Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin

Maria H. Sjogren*, Robert Sjogren, Michael F. Lyons, Michael Ryan, John Santoro, Coleman Smith, K. Rajender Reddy, Herbert Bonkovsky, Brooke Huntley, Sima Faris-Young

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.

Original languageEnglish
Pages (from-to)1540-1547
Number of pages8
JournalDigestive Diseases and Sciences
Issue number6
StatePublished - Jun 2007
Externally publishedYes


  • African-American
  • Depression
  • Interferon alfacon-1
  • Quality of life
  • Viral hepatitis
  • Viral load


Dive into the research topics of 'Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin'. Together they form a unique fingerprint.

Cite this